San Ramon, CA – June 15, 2009
–
Nextrials, Inc.
, a leader in clinical research software and services, today announced it has received Frost & Sullivan’s 2009 Clinical Trials Management Product Innovation of the Year Award. In presenting the award, Frost & Sullivan recognized the company’s flagship electronic data capture (EDC) and clinical trial management platform, Prism®, for its ability to integrate with electronic health records (EHR) systems, thereby improving patient data exchange between the clinical trial and the healthcare setting.
The Frost & Sullivan Award for Product Innovation is presented annually to the company that has demonstrated excellence in new products and technologies within its industry. In this instance, Frost & Sullivan praised Nextrials as a pioneer in implementing and enforcing healthcare IT standards, helping to overcome the hurdles that a typical EHR system faces in providing accurate information required for clinical trials.
“With the U.S. Government’s emphasis on improving the efficiency of the healthcare system, including healthcare IT, Nextrials is best positioned to play a key role in the process of moving novel therapeutics from the bench to the bedside,” said Sudeep Basu, Ph.D., of Frost & Sullivan. “Linking EHR systems to EDC systems can help achieve this critical objective by enabling healthcare organizations to provide the accurate information and audit trails required for clinical trials.”
“This award validates Nextrials’ emphasis on utilizing new industry standards to support interoperability,” noted James Rogers, co-founder and CEO of Nextrials. “We’re very pleased to be recognized for our efforts to promote national standards and, ultimately, the seamless integration of data capture platforms used in the clinical trial setting with the platforms used in healthcare organizations to create and manage electronic medical records.”
Those attending the 45th Annual Meeting of the Drug Information Association, being held at the San Diego (CA) Convention Center June 21-25, can view a demonstration of Prism in the Nextrials’ booth (#1302). Visitors can also see a live healthcare link demonstration featuring Nextrials’ Prism that showcases data interoperability between clinical research and clinical care in the Clinical Data Interchange Standards Consortium (CDISC) booth (#1915).
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan’s Growth Partnerships, visit
http://www.frost.com
.
About Nextrials
Founded by pharmaceutical researchers in 1999, Nextrials offers today’s most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,200 research sites to streamline the initiation and management of clinical trials. The company is headquartered in the San Francisco Bay area. For more information, visit
www.nextrials.com
or call 925-355-3000. A podcast by co-founder and CEO James Rogers on the incorporation of electronic health records into the clinical trial process is also available at
http://pharmavoice.com/podcasts
.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.